All In Biotech

Drug Trial Radar · NCT04808531

NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers

NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial

Last checked: Nov 19, 2026Latest source record: Apr 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

360

Planned (sponsor's estimate)

Start

Nov 2023

Primary completion

Feb 2024

Study completion Jun 2024

Sponsor

Lead sponsor
Medlab ClinicalIndustry
Sponsor type
Industry
Collaborators
Emerald Clinical Inc.; WriteSource Medical Pty Ltd
First posted
Mar 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-centre, long term, double blind, clinical protocol for NanaBis™ as a monotherapy treatment in participants 18-75 years of age with cancer related pain.

Conditions

  • Cancer Related Pain

Interventions

  • NanaBis™Drug

    NanaBis™ is a nanoparticle water soluble equimolar solution of d9-THC \& CBD. One dose is equivalent to 2 actuations of the pump delivering 280 µL volume containing 2.5 mg d9-THC and 2.5 mg CBD

  • Oxycodone CRDrug

    Oxycodone CR tablet is an opioid agonist supplied in 10 mg, 15 mg, 20 mg, 30 mg,40 mg, 60 mg and 80 mg tablets for oral administration. The tablet strengths describe the amount of oxycodone per tablet as the hydrochloride salt.

  • Placebo SprayDrug

    Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.

  • Placebo TabletDrug

    Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.

  • Oxycodone IRDrug

    Oxycodone immediate release (IR) tablet or capsule or oral solution used as breakthrough analgesia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Significant changes in responders with NanaBis™ spray over placebo (p<0.05)Time frame: 6 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.